TROPIFEXOR



NAME OF DRUG : TROPIFEXOR

ALSO KNOWN AS : LJN452

LABORATORY : NOVARTIS

STATUS AND ADVANCEMENT

Type of drug : non-BA FXR agonist

Clinical trials advancement : Recruiting Phase 2b

Estimated time to market : 90 months.

LABORATORY ABSTRACT ON THE DRUG

LJN452, a non-bile acid FXR agonist, is our lead clinical candidate for NASH: • Reduced steatosis & fibrosis in animal models • Favorable safety profile in first- in-human studies ? First proof-of-concept in primary biliary cirrhosis to start in 2015

RECENT NEWS ON TROPIFEXOR

2018-04-18 : Novartis expands development programs for NASH through clinical collaboration with Allergan

SOME PUBLICATIONS RELATED WITH TROPIFEXOR

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH TROPIFEXOR


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE